David Moskowitz - Photocure ASA Head Relations
| PHCUF Stock | USD 5.17 0.00 0.00% |
Insider
David Moskowitz is Head Relations of Photocure ASA
| Phone | 47 22 06 22 10 |
| Web | https://www.photocure.com |
Photocure ASA Management Efficiency
The company has return on total asset (ROA) of (0.0309) % which means that it has lost $0.0309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1567) %, meaning that it generated substantial loss on money invested by shareholders. Photocure ASA's management efficiency ratios could be used to measure how well Photocure ASA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Betty Swartz | Esperion Therapeutics | N/A | |
| Eiry MD | Neurocrine Biosciences | 61 | |
| Benjamin MBA | Esperion Therapeutics | 39 | |
| MD FACC | Esperion Therapeutics | 59 | |
| Jude Onyia | Neurocrine Biosciences | 61 | |
| Eric RPh | Esperion Therapeutics | 53 | |
| Jason Rickard | Ironwood Pharmaceuticals | 53 | |
| Jack Hoblitzell | Assertio Therapeutics | N/A | |
| Beth Calitri | Ironwood Pharmaceuticals | N/A | |
| Ajay Patel | Assertio Therapeutics | 41 | |
| Kenneth Fiorelli | Esperion Therapeutics | N/A | |
| Daniel Peisert | Assertio Therapeutics | 49 | |
| John Minardo | Ironwood Pharmaceuticals | 49 | |
| Sravan Emany | Ironwood Pharmaceuticals | 46 | |
| Ben MBA | Esperion Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0309 |
Photocure ASA Leadership Team
Elected by the shareholders, the Photocure ASA's board of directors comprises two types of representatives: Photocure ASA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Photocure. The board's role is to monitor Photocure ASA's management team and ensure that shareholders' interests are well served. Photocure ASA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Photocure ASA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tolv Hillestad, Group Controller | ||
| Erik Dahl, Chief Officer | ||
| Patricia Kelly, VP HR | ||
| David Moskowitz, Head Relations | ||
| Daniel Schneider, President CEO | ||
| Anders Neijber, Clinical Affairs | ||
| Kari MD, Head Devel | ||
| Geoffrey Coy, VP Operations |
Photocure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Photocure ASA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0309 | |||
| Profit Margin | (0.20) % | |||
| Operating Margin | (0.1) % | |||
| Current Valuation | 277.44 M | |||
| Shares Outstanding | 27.11 M | |||
| Shares Owned By Insiders | 2.98 % | |||
| Shares Owned By Institutions | 48.69 % | |||
| Price To Earning | 329.14 X | |||
| Price To Book | 5.72 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Photocure Pink Sheet
Photocure ASA financial ratios help investors to determine whether Photocure Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Photocure with respect to the benefits of owning Photocure ASA security.